Tailoring Dendritic Cell Diversity To Advance Effective Immunotherapies
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Dendritic cells (DCs) constitute the first line of defense against infection and cancer. To achieve this feat, DC have evolved into a sophisticated network of specialized subtypes, although how this diversification process occurs is yet to be fully clarified. We have uncovered a new molecule, termed DC-SCRIPT, which has a key role in establishing the DC network, specialization and function. This offers crucial new clues as to how to manipulate DCs to either boost or dampen the immune system.